Skedgel C - Search Results

1

Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.

Skedgel C, Rayson D, Dewar R, Younis T. Skedgel C, et al. Breast. 2007 Jun;16(3):252-61. doi: 10.1016/j.breast.2006.12.002. Epub 2007 Jan 4. Breast. 2007. PMID: 17207623

2

Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.

Younis T, Rayson D, Sellon M, Skedgel C. Younis T, et al. Among authors: skedgel c. Breast Cancer Res Treat. 2008 Sep;111(2):261-7. doi: 10.1007/s10549-007-9770-x. Epub 2007 Oct 5. Breast Cancer Res Treat. 2008. PMID: 17914669

3

The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.

Skedgel C, Rayson D, Younis T. Skedgel C, et al. Value Health. 2009 Jul-Aug;12(5):641-8. doi: 10.1111/j.1524-4733.2009.00511.x. Value Health. 2009. PMID: 19490562 Free article. Clinical Trial.

4

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.

Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T. Lamond NW, et al. Among authors: skedgel c. Breast Cancer Res Treat. 2012 Jun;133(3):1115-23. doi: 10.1007/s10549-012-1989-5. Epub 2012 Feb 24. Breast Cancer Res Treat. 2012. PMID: 22361999

5

Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

Skedgel C, Rayson D, Younis T. Skedgel C, et al. Support Care Cancer. 2016 Jan;24(1):387-394. doi: 10.1007/s00520-015-2805-7. Epub 2015 Jun 17. Support Care Cancer. 2016. PMID: 26081595

6

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.

Skedgel C, Rayson D, Dewar R, Younis T. Skedgel C, et al. Breast Cancer Res Treat. 2007 Mar;101(3):325-33. doi: 10.1007/s10549-006-9299-4. Epub 2006 Aug 2. Breast Cancer Res Treat. 2007. PMID: 16897433

7

Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.

Younis T, Rayson D, Dewar R, Skedgel C. Younis T, et al. Among authors: skedgel c. Ann Oncol. 2007 Feb;18(2):293-8. doi: 10.1093/annonc/mdl410. Epub 2006 Nov 9. Ann Oncol. 2007. PMID: 17095569 Free article.

8

Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?

Skedgel C, Rayson D, Younis T. Skedgel C, et al. Ann Oncol. 2013 Jul;24(7):1834-1840. doi: 10.1093/annonc/mdt069. Epub 2013 Mar 19. Ann Oncol. 2013. PMID: 23510987 Free article.

9

Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.

Younis T, Rayson D, Jovanovic S, Skedgel C. Younis T, et al. Among authors: skedgel c. Breast Cancer Res Treat. 2016 Oct;159(3):425-32. doi: 10.1007/s10549-016-3954-1. Epub 2016 Aug 30. Breast Cancer Res Treat. 2016. PMID: 27572552 Review.

10

Is trastuzumab a cost-effective treatment for breast cancer?

Younis T, Skedgel C. Younis T, et al. Among authors: skedgel c. Expert Rev Pharmacoecon Outcomes Res. 2008 Oct;8(5):433-42. doi: 10.1586/14737167.8.5.433. Expert Rev Pharmacoecon Outcomes Res. 2008. PMID: 20528328

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters